Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors

This publication has 16 references indexed in Scilit:

• Yttrium-90 DOTATOC: first clinical results
  European Journal of Nuclear Medicine and Molecular Imaging, 1999
• In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. a new somatostatin analog with improved target tissue uptake
  Nuclear Medicine and Biology, 1999
• Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
  Annals of Oncology, 1999
• EXPERIENCES WITH HIGH DOSE RADIOPEPTIDE THERAPY
  Health Physics, 1999
• The somatostatin receptor-targeted radiotherapeutic [ 90 Y-DOTA- d Phe 1 ,Tyr 3 ]octreotide ( 90 Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with188Re-RC-160, a directly-radiolabeled somatostatin analogue
  International Journal of Cancer, 1996
• Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy
  European Journal of Nuclear Medicine and Molecular Imaging, 1995
• Radiotherapy with a Radiolabeled Somatostatin Analogue, [¹¹¹In‐DTPA‐d‐Phe¹]‐Octreotide
  Annals of the New York Academy of Sciences, 1994
• Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide
  European Journal of Nuclear Medicine and Molecular Imaging, 1993
• Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors
  New England Journal of Medicine, 1990